BR0309875A - métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto - Google Patents

métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto

Info

Publication number
BR0309875A
BR0309875A BRPI0309875-3A BR0309875A BR0309875A BR 0309875 A BR0309875 A BR 0309875A BR 0309875 A BR0309875 A BR 0309875A BR 0309875 A BR0309875 A BR 0309875A
Authority
BR
Brazil
Prior art keywords
methods
nervous system
peripheral nervous
compositions
system disorders
Prior art date
Application number
BRPI0309875-3A
Other languages
English (en)
Inventor
Abraham Fisher
Nira Bar-Ner
Yishai Karton
Original Assignee
Israel Inst For Biolog Res Isr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Israel Inst For Biolog Res Isr filed Critical Israel Inst For Biolog Res Isr
Publication of BR0309875A publication Critical patent/BR0309875A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)

Abstract

"MéTODOS E COMPOSIçõES PARA TRATAMENTO DE DISTúRBIOS DO SISTEMA NERVOSO PERIFéRICO E NOVOS COMPOSTOS úTEIS PARA ISTO". São fornecidos métodos para o tratamento de doenças envolvendo disfunção do sistema nervoso central e periférico compreendendo administração de um ou mais compostos espiro. Também são fornecidas composições farmacêuticas úteis em tais métodos, compostos para uso na preparação de tais composições farmacêuticas, processos para preparação de compostos úteis na prática de tais métodos, e alguns dos tais novos compostos per se.
BRPI0309875-3A 2002-05-03 2003-05-01 métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto BR0309875A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37743302P 2002-05-03 2002-05-03
PCT/IL2003/000357 WO2003092580A2 (en) 2002-05-03 2003-05-01 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor

Publications (1)

Publication Number Publication Date
BR0309875A true BR0309875A (pt) 2007-04-10

Family

ID=29401496

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0309875-3A BR0309875A (pt) 2002-05-03 2003-05-01 métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto

Country Status (15)

Country Link
US (3) US7439251B2 (pt)
EP (1) EP1507765A4 (pt)
JP (2) JP4584706B2 (pt)
KR (2) KR100998804B1 (pt)
CN (1) CN1662506A (pt)
AR (1) AR039965A1 (pt)
AU (1) AU2003223093B2 (pt)
BR (1) BR0309875A (pt)
CA (1) CA2484599A1 (pt)
IL (1) IL164857A (pt)
MX (1) MXPA04010921A (pt)
NZ (2) NZ536610A (pt)
TW (1) TWI330640B (pt)
WO (1) WO2003092580A2 (pt)
ZA (1) ZA200408861B (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173618B2 (en) * 2003-07-25 2012-05-08 University Of Massachusetts Formulations for reducing neuronal degeneration
WO2006044497A2 (en) * 2004-10-13 2006-04-27 Merck & Co., Inc. Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
ITRM20040606A1 (it) * 2004-12-13 2005-03-13 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina per il trattamento della sindrome fibromialgica.
US8211904B2 (en) * 2005-07-18 2012-07-03 Merck, Sharp & Dohme Corp. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007013661A1 (ja) * 2005-07-26 2007-02-01 Senju Pharmaceutical Co., Ltd. 眼科用経皮吸収型製剤
GB0607949D0 (en) * 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
ITMI20061279A1 (it) * 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche Agonisti nicotinici selettivi per il sottotipo recettoriale alfa7,procedimento per la loro preparazione e relative composizioni farmaceutiche
AU2007293416A1 (en) * 2006-09-07 2008-03-13 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
CA2668065A1 (en) * 2006-10-30 2008-05-08 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
AU2007342368A1 (en) * 2007-01-04 2008-07-17 Merck & Co., Inc. Bicyclic spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
US8597640B2 (en) * 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
US8614324B2 (en) * 2008-10-31 2013-12-24 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic
US9340558B2 (en) 2007-11-02 2016-05-17 Pain Therapeutics Inc. Filamin a binding anti-inflammatory and analgesic
US8653068B2 (en) 2009-10-30 2014-02-18 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic
RU2476431C2 (ru) 2008-01-18 2013-02-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Конденсированное производное аминодигидротиазина
US8309577B2 (en) 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
JP5444240B2 (ja) * 2008-07-28 2014-03-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
EP2318416B1 (en) * 2008-07-28 2013-09-04 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
KR20110076965A (ko) * 2008-09-30 2011-07-06 에자이 알앤드디 매니지먼트 가부시키가이샤 신규한 축합 아미노 디하이드로티아진 유도체
WO2010051497A1 (en) * 2008-10-31 2010-05-06 Pain Therapeutics, Inc. Filamin a binding anti-inflammatory and analgesic
US8580808B2 (en) * 2009-10-30 2013-11-12 Pain Therapeutic, Inc. Filamin A-binding anti-inflammatory analgesic
AU2010207486B2 (en) 2009-01-26 2013-03-07 Israel Institute For Biological Research Bicyclic heterocyclic spiro compounds
US9034891B2 (en) 2009-01-26 2015-05-19 Israel Institute For Biological Research Bicyclic heterocyclic spiro compounds
US20100330607A1 (en) * 2009-06-24 2010-12-30 Photoswitch Biosciences, Inc. Photoswitch-enabled ion channel assay system
PT3061821T (pt) * 2009-07-22 2019-09-05 PureTech Health LLC Composições para tratamento de distúrbios melhorados por ativação de recetores muscarínicos
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
US8278320B2 (en) 2009-10-28 2012-10-02 Bristol-Myers Squibb Company Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands
US8507516B2 (en) 2009-10-28 2013-08-13 Bristol-Myers Squibb Company Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands
US8580809B2 (en) * 2009-10-30 2013-11-12 Pain Therapeutics, Inc. Filamin A-binding anti-inflammatory analgesic
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
ES2712752T3 (es) 2009-11-12 2019-05-14 Pharmatrophix Inc Formas cristalinas de compuestos miméticos de neurotrofina y sus sales
EP2556076A2 (en) * 2010-04-09 2013-02-13 Pfizer Inc. Novel sultam compounds
CN103025744A (zh) * 2010-04-30 2013-04-03 百时美施贵宝公司 作为α-7烟碱乙酰胆碱受体配体前药的氮杂二环胺N-氧化物化合物
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
TWI632921B (zh) * 2011-10-19 2018-08-21 大塚製藥股份有限公司 口服溶液
US20130331330A1 (en) * 2012-06-08 2013-12-12 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating alzheimer's disease and other tauopathies with inhibitors of microtubule affinity regulating kinase
ES2716049T3 (es) 2012-07-13 2019-06-07 Pain Therapeutics Inc Un método para inhibir la fosforilación de tau
JP6566867B2 (ja) 2012-07-13 2019-08-28 ペイン セラピューティクス インコーポレイテッド 生きている患者でのアルツハイマー病アッセイ
WO2014141110A2 (en) * 2013-03-14 2014-09-18 Curadev Pharma Pvt. Ltd. Aminonitriles as kynurenine pathway inhibitors
US9433604B2 (en) 2013-10-08 2016-09-06 Pain Therapeutics Inc. Method for inhibiting growth of cancer cells
CN103923105B (zh) * 2014-04-17 2016-08-24 北京大学 2-中氮茚甲酰胺类化合物及其制备和用途
CN105085348B (zh) * 2014-05-20 2017-07-25 浙江大学 一种苯甲酸硫酯类化合物及其应用
CA2978214A1 (en) * 2015-03-06 2016-09-15 Chase Pharmaceuticals Corporation Peripheral-anticholinergic muscarinic agonist combination
US10307409B2 (en) 2015-03-06 2019-06-04 Chase Pharmaceuticals Corporation Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system
MX383581B (es) 2016-10-05 2025-03-14 Nsc Therapeutics Gmbh Polimorfos cristalinos de un agonista del receptor muscarinico de acetilcolina.
US11948662B2 (en) * 2017-02-17 2024-04-02 The Regents Of The University Of California Metabolite, annotation, and gene integration system and method
US12201619B2 (en) 2018-03-22 2025-01-21 Nsc Therapeutics Gmbh Compounds and methods for use in the treatment of microglia-mediated disorders
KR102408292B1 (ko) 2018-09-28 2022-06-10 카루나 세러퓨틱스 인코포레이티드 무스카린성 수용체 활성화에 의해 개선된 장애의 치료를 위한 조성물 및 방법
WO2021228123A1 (zh) * 2020-05-12 2021-11-18 北京广为医药科技有限公司 调节nmda受体活性的化合物、其药物组合物及用途
KR102245391B1 (ko) 2020-10-08 2021-05-18 강현주 케이블 벤딩장치 및 그를 구비하는 케이블 자동 제조 시스템

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE331282B (pt) * 1966-12-16 1970-12-21 Yoshitomi Pharmaceutical
US3723442A (en) 1970-12-31 1973-03-27 Yoshitomi Pharmaceutical 3-oxo-1-oxa-4,8-diazaspiro(4.5)decanes
US3897425A (en) * 1974-04-01 1975-07-29 Interx Research Corp 3-Chloro-tetrahydro-1,3-oxazines or oxazolidines
JPS60184012A (ja) 1984-03-02 1985-09-19 Yoshitomi Pharmaceut Ind Ltd 免疫調整剤
US4855290A (en) 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
US4981858A (en) 1987-08-13 1991-01-01 State Of Israel, Represented By The Prime Minister's Office, Israel Institute For Biological Research Optical isomers
US4876260A (en) 1987-10-28 1989-10-24 State Of Israel, Israel Institute Of Biological Research Oxathiolanes
US4900830A (en) 1987-10-28 1990-02-13 Israel Institute For Biological Research Process for labelling sulfur-containing compounds
US5053412A (en) 1990-04-10 1991-10-01 Israel Institute For Biological Research Spiro nitrogen-bridged heterocyclic compounds
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
US5407938A (en) 1990-04-10 1995-04-18 Israel Institute For Biological Research Certain 1-methyl-piperidine-4-spiro-4'-(1'-3'-oxazolines) and corresponding -(1',3' thiazolines)
US5534520A (en) * 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
US6277874B1 (en) 1996-07-09 2001-08-21 University Of Cincinnati And Apologic, Incorporated Methods for the treatment of apolipoprotein E related diseases
TW453999B (en) * 1997-06-27 2001-09-11 Fujisawa Pharmaceutical Co Benzimidazole derivatives
CA2304505A1 (en) 1997-09-24 1999-04-01 Nova Molecular, Inc. Methods for increasing apoe levels for the treatment of neurodegenerative disease
GB9916562D0 (en) * 1999-07-14 1999-09-15 Pharmacia & Upjohn Spa 3-Arylsulfonyl-2-(substituted-methyl) propanoic acid derivatives as matrix metalloproteinase inhibitora
DE19962543A1 (de) * 1999-12-23 2001-07-05 Degussa Chromatographische Enantiomerentrennung von bicyclischen Lactamen

Also Published As

Publication number Publication date
NZ536610A (en) 2009-02-28
WO2003092580A2 (en) 2003-11-13
WO2003092580B1 (en) 2004-06-24
US20060052406A1 (en) 2006-03-09
KR20100075700A (ko) 2010-07-02
NZ560368A (en) 2008-11-28
JP4759649B2 (ja) 2011-08-31
AU2003223093A1 (en) 2003-11-17
KR100998804B1 (ko) 2010-12-06
AU2003223093B2 (en) 2010-02-04
US7049321B2 (en) 2006-05-23
MXPA04010921A (es) 2005-05-27
JP4584706B2 (ja) 2010-11-24
WO2003092580A3 (en) 2004-05-06
CN1662506A (zh) 2005-08-31
IL164857A (en) 2010-12-30
ZA200408861B (en) 2006-07-26
CA2484599A1 (en) 2003-11-13
JP2010184946A (ja) 2010-08-26
JP2005530742A (ja) 2005-10-13
EP1507765A4 (en) 2006-11-02
EP1507765A2 (en) 2005-02-23
TW200404808A (en) 2004-04-01
US7439251B2 (en) 2008-10-21
TWI330640B (en) 2010-09-21
KR101027570B1 (ko) 2011-04-06
AR039965A1 (es) 2005-03-09
US20080306103A1 (en) 2008-12-11
KR20050025168A (ko) 2005-03-11
US20040044018A1 (en) 2004-03-04
IL164857A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
DE60321929D1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
BRPI0307351B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
FI963294A0 (fi) Naftyyliamidit keskushermostoaineina
AR002705A1 (es) Un nuevo compuesto de indolina, un proceso para su preparacion y composiciones farmaceuticas que lo contienen.
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
ATE284690T1 (de) Antithrombotische diamine
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
BRPI0411582A (pt) substáncias terapêuticas contendo boro hidroliticamente resistentes e método de uso
TR200201094T2 (tr) Farmasötik maddeler olarak bisiklik amino asitler
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
BRPI0410316A (pt) composto, composição farmacêutica, uso dos compostos, e, método de tratamento de distúrbios mediados por vr1 e para o tratamento de distúrbios de dores
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
YU75603A (sh) Dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja
IL163951A0 (en) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
ATE457027T1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on- verbindungen zur behandlung von fettsucht
DK1194415T3 (da) Nye piperazinylalkylthiopyrimidinderivater, farmaceutiske sammensætninger indeholdende disse samt en fremgangsmåde til deres fremstilling
BR0111897A (pt) Composto, método para tratar um indivìduo afligido por alguns distúrbios dos sistemas nervosos periférico e central, composição farmacêutica, e, uso de um composto
BR0112131A (pt) Composições farmacêuticas e métodos para uso
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
BR0112130A (pt) Composições farmacêuticas e métodos para uso
BR9908838A (pt) Uso de um glicocorticóide, processeo para tratar glomerulonefrite aguda ou crÈnica, e, composição farmacêutica para tratar glomerulonefrite
WO2002076930A3 (en) Substituted diarylureas as stimulators for fas-mediated apoptosis
BRPI0410026A (pt) derivados de 3-amino-croman quinolina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL:C07D 221/20, A61K 31/4523, A61P 25/00

Ipc: C07D 221/20 (2011.01), A61K 31/4523 (2011.01)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2157 DE 08/05/2012.